Pelthos Therapeutics Inc. Deferred Income Tax Expense (Benefit)
Pelthos Therapeutics Inc. (PTHS) reported Deferred Income Tax Expense (Benefit) of -$7.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-19
- Pelthos Therapeutics Inc. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was -$6.92M.
- Pelthos Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2025 was -$7.39M.
- Pelthos Therapeutics Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2025-12-31 | -$6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$7.39M 10-K · filed 2026-03-19 | |
| 2025-09-30 | -$465.00K 10-Q · filed 2025-11-13 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |